According to a survey in The Journal of Headache and Pain, chronic pain is the most common reason Americans have tried wellness products derived from cannabis. The FDA makes it explicitly clear that cannabis companies are not allowed to promote CBD products with disease terms like pain, insomnia, or anxiety. Persistent issues like inflammation can impact the quality of life and contribute to serious illnesses. In 2012, the Journal of Experimental Medicine reported that CBD treatment suppressed chronic inflammation and neuropathic pain in lab rats and mice. Other recent studies have also explored CBD’s potential for the treatment of inflammation, high blood pressure, and more. In 2018, the FDA approved the use of the CBD oil, Epidiolex, to treat two forms of epilepsy. A review by Neurotherapeutics also examines the compound’s potential to offer relief for individuals suffering from a variety of anxiety disorders.